Last reviewed · How we verify
verapamil controlled release
At a glance
| Generic name | verapamil controlled release |
|---|---|
| Also known as | Verelan PM, verapamil controlled release capsule |
| Sponsor | Synerx Pharma, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation (PHASE4)
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation (PHASE4)
- Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg (PHASE1)
- Ranolazine and Microvascular Angina by PET in the Emergency Department (PHASE4)
- Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- verapamil controlled release CI brief — competitive landscape report
- verapamil controlled release updates RSS · CI watch RSS
- Synerx Pharma, LLC portfolio CI